743 related articles for article (PubMed ID: 16139186)
1. Opioid switch in palliative care, opioid choice by clinical need and opioid availability.
Müller-Busch HC; Lindena G; Tietze K; Woskanjan S
Eur J Pain; 2005 Oct; 9(5):571-9. PubMed ID: 16139186
[TBL] [Abstract][Full Text] [Related]
2. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
3. Frequency, indications, outcomes, and predictive factors of opioid switching in an acute palliative care unit.
Mercadante S; Ferrera P; Villari P; Casuccio A; Intravaia G; Mangione S
J Pain Symptom Manage; 2009 Apr; 37(4):632-41. PubMed ID: 19345298
[TBL] [Abstract][Full Text] [Related]
4. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.
Mercadante S; Porzio G; Ferrera P; Fulfaro F; Aielli F; Verna L; Villari P; Ficorella C; Gebbia V; Riina S; Casuccio A; Mangione S
Eur J Pain; 2008 Nov; 12(8):1040-6. PubMed ID: 18353696
[TBL] [Abstract][Full Text] [Related]
5. Outcomes after intravenous opioids in emergency patients: a prospective cohort analysis.
O'Connor AB; Zwemer FL; Hays DP; Feng C
Acad Emerg Med; 2009 Jun; 16(6):477-87. PubMed ID: 19426295
[TBL] [Abstract][Full Text] [Related]
6. Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine.
Wirz S; Wittmann M; Schenk M; Schroeck A; Schaefer N; Mueller M; Standop J; Kloecker N; Nadstawek J
Eur J Pain; 2009 Aug; 13(7):737-43. PubMed ID: 18977159
[TBL] [Abstract][Full Text] [Related]
7. Opioid rotation from morphine to fentanyl in delirious cancer patients: an open-label trial.
Morita T; Takigawa C; Onishi H; Tajima T; Tani K; Matsubara T; Miyoshi I; Ikenaga M; Akechi T; Uchitomi Y;
J Pain Symptom Manage; 2005 Jul; 30(1):96-103. PubMed ID: 16043013
[TBL] [Abstract][Full Text] [Related]
8. A prospective study evaluating the response of patients with unrelieved cancer pain to parenteral opioids.
Enting RH; Oldenmenger WH; van der Rijt CC; Wilms EB; Elfrink EJ; Elswijk I; Sillevis Smitt PA
Cancer; 2002 Jun; 94(11):3049-56. PubMed ID: 12115396
[TBL] [Abstract][Full Text] [Related]
9. Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine.
Mercadante S; Villari P; Ferrera P; Porzio G; Aielli F; Verna L; Casuccio A
J Pain Symptom Manage; 2006 Aug; 32(2):175-9. PubMed ID: 16877185
[TBL] [Abstract][Full Text] [Related]
10. Morphine and alternative opioids in cancer pain: the EAPC recommendations.
Hanks GW; Conno F; Cherny N; Hanna M; Kalso E; McQuay HJ; Mercadante S; Meynadier J; Poulain P; Ripamonti C; Radbruch L; Casas JR; Sawe J; Twycross RG; Ventafridda V;
Br J Cancer; 2001 Mar; 84(5):587-93. PubMed ID: 11237376
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety profile of a single dose of hydromorphone compared with morphine in older adults with acute, severe pain: a prospective, randomized, double-blind clinical trial.
Chang AK; Bijur PE; Baccelieri A; Gallagher EJ
Am J Geriatr Pharmacother; 2009 Feb; 7(1):1-10. PubMed ID: 19281935
[TBL] [Abstract][Full Text] [Related]
12. The use of opioids for breakthrough pain in acute palliative care unit by using doses proportional to opioid basal regimen.
Mercadante S; Villari P; Ferrera P; Mangione S; Casuccio A
Clin J Pain; 2010 May; 26(4):306-9. PubMed ID: 20393265
[TBL] [Abstract][Full Text] [Related]
13. Opioid use by patients in an orthopedics spine clinic.
Mahowald ML; Singh JA; Majeski P
Arthritis Rheum; 2005 Jan; 52(1):312-21. PubMed ID: 15641058
[TBL] [Abstract][Full Text] [Related]
14. Assessment of dosing frequency of sustained-release opioid preparations in patients with chronic nonmalignant pain.
Gallagher RM; Welz-Bosna M; Gammaitoni A
Pain Med; 2007; 8(1):71-4. PubMed ID: 17244106
[TBL] [Abstract][Full Text] [Related]
15. Modeling the economic and health consequences of managing chronic osteoarthritis pain with opioids in Germany: comparison of extended-release oxycodone and OROS hydromorphone.
Ward A; Bozkaya D; Fleischmann J; Dubois D; Sabatowski R; Caro JJ
Curr Med Res Opin; 2007 Oct; 23(10):2333-45. PubMed ID: 17697453
[TBL] [Abstract][Full Text] [Related]
16. [Parenteral opioids in end-of-life care in cancer patients].
Hattori S; Kimura N; Takatani J; Noguchi T
Gan To Kagaku Ryoho; 2005 Feb; 32(2):161-6. PubMed ID: 15751626
[TBL] [Abstract][Full Text] [Related]
17. [Use of opioids against severe cancer pain].
Borchgrevink PC; Klepstad P; Kongsgaard UE; Kaasa S
Tidsskr Nor Laegeforen; 2004 Feb; 124(3):337-8. PubMed ID: 14963506
[No Abstract] [Full Text] [Related]
18. Safety and effectiveness of intravenous morphine for episodic (breakthrough) pain using a fixed ratio with the oral daily morphine dose.
Mercadante S; Villari P; Ferrera P; Bianchi M; Casuccio A
J Pain Symptom Manage; 2004 Apr; 27(4):352-9. PubMed ID: 15050663
[TBL] [Abstract][Full Text] [Related]
19. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study.
Simpson DM; Messina J; Xie F; Hale M
Clin Ther; 2007 Apr; 29(4):588-601. PubMed ID: 17617282
[TBL] [Abstract][Full Text] [Related]
20. [Nociceptive cancer pain in adult patients: statement about guidelines related to the use of antinociceptive medicine].
Binhas M; Krakowski I; Marty J
Ann Fr Anesth Reanim; 2007 Jun; 26(6):502-15. PubMed ID: 17560755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
